大剂量糖皮质激素静脉冲击治疗甲状腺相关眼病的研究

甲状腺相关性眼病(TAO)是一种器官特异性自身免疫性疾病,临床表现为多种眼征,目前对本病的治疗尚不满意。近10余年来,对糖皮质激素治疗TAO的机制有了进一步的认识,而大剂量糖皮质激素静脉冲击方案在治疗TAO方面显示了较大的优越性,除眼球突出以及由此导致的复视效果并不肯定外,其对眼部软组织炎症、视神经病变、眼外肌功能障碍者效果优良,对于病程较短、病情较重的活动期患者尤然;而且,这种疗法副作用少,患者依从性较佳,值得临床上进一步推广与探索。

Study Progress of High Dose Intravenous Glucocorticoid Pulse Therapy in the Treatment of Thyroidassociated Ophthalmopathy

Thyroid-associated ophthalmopathy(TAO)is an organ-specific autoimmune process with a variety of clinical ocular symptoms and signs.There is still not satisfactory treatment for this disease at present.In recent 10 years,with further acknowledgement in the mechanism of glucocorticoid in treating TAO,high dose intravenous glucocorticoid pulse therapy has showed its huge advantages in treating this disease,especially including soft tissue inflammation in ocular region,optic neuropathy,oculorotatory muscles dysfunction although its effect in ophthalmoptosis and diplopia resulting from it is not affirmative yet.Patients in active stage with short course and severe pathogenetic condition will benefit from the method most.This treatment with few side effects and fine compliance of patients is worth further applying and research.